Authors

Nima Sharifi, MD, director, discusses the methodologies utilized when evaluating the correlation between gut microbiome and fatal prostate cancer.

Experts discuss the challenges and barriers in early referral for chimeric antigen receptor T-cell therapy (CAR T) and how post–CAR T follow-up care is managed between academic and community settings.

The panel closes by reviewing the patient case once more and shares clinical pearls on the treatment of patients with GVHD.

Rima Patel, MD, discusses the associations between the 21-gene oncotype DX recurrence score, Ki-67, and race in early-stage breast cancer.

RAD51 may serve as a functional biomarker to help guide olaparib use in HER2-negative metastatic breast cancer harboring BRCA1/2 or PALB2 mutations.

Laleh Melstrom, MD, MS, discusses using molecular testing to guide treatment selection for patient with gastrointestinal cancers.

Panelists emphasize that as circulating tumor DNA (ctDNA) testing becomes more integrated into clinical practice, careful interpretation, tailored testing schedules, and ongoing provider education are key to its effective use in personalized breast cancer care.

In this seventh episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, walk through a timeline of FDA approvals of immunotherapy approaches in gynecologic oncology and discuss associated toxicities to be aware of as well as how to manage them.

Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.

Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, and David Dingli, MD, PhD, discuss unmet needs to address in the management of PNH.

Dr Halmos discusses the VISION trial, the significance of MET exon 14 skipping mutations in NSCLC, and the clinical utility of tepotinib in this disease.

Dr. Martin Reck presents the five year update of CheckMate 9LA (NCT03215706) and exploratory analysis of efficacy in patients who discontinued treatment due to treatment related adverse events in patients with metastatic non-small lung cancer.

Fenghuang Zhan, MD, PhD, and John D. Shaughnessy, Jr, PhD, discuss the need for a paradigm shift in the treatment of multiple myeloma with the integration of immunotherapy.

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

Segment III explores how clinicians approach second-line therapy in follicular lymphoma, particularly as new options challenge traditional standards. Dr. Mehta reviews how CD20-directed therapies have historically anchored relapse treatment but notes the shift toward more diverse targets, including CD3 (via bispecific antibodies) and CD19 (via tafasitamab and other emerging agents). This expansion raises important clinical questions around target sequencing, resistance, and whether using a target early may “burn” it for future lines of therapy. The discussion highlights the role of bispecific antibodies, CAR T-cell therapy, and CD19-based agents, along with practical considerations such as infusion requirements, monitoring demands, and access to treatment centers with specialized capabilities. Dr. Mehta explains how academic-community partnerships influence real-world treatment pathways, especially for therapies with more complex toxicity profiles like cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). NP Bailey contributes perspective on patient logistics, including distance to treatment centers, social support needs, and how the complexity of treatment may shape patient decision-making. She emphasizes the importance of aligning therapy selection with patient lifestyle and functional status, a theme that recurs throughout the program. This segment underscores the increasingly individualized nature of second-line therapy, where clinicians must integrate disease biology, treatment history, patient comorbidities, and practical feasibility. As the faculty outline, modern management requires balancing efficacy with safety, accessibility, and long-term planning, ensuring that patients receive not only effective but sustainable care.

Jose A. Karam, MD, FACS, discusses key takeaways from the 2023 International Kidney Cancer Symposium.

Steven Park, MD, discusses the mechanism of action of tazemetostat and the rationale for the phase 3 SYMPHONY-1 trial in patients with relapsed follicular lymphoma.

How Texas Colon & Rectal Specialists enhance outcomes, experiences, and efficiency data-driven care to improve patient outcome.

Olalekan O. Oluwole, MD, MPH, discusses how AE assessment could guide post-infusion monitoring periods and outpatient axi-cel administration in LBCL.